Overview

Quality of Life in New Treatable Therapy as Rabeprazole Option for Refractory Reflux Esophagitis

Status:
Completed

Trial end date:
2013-08-01

Target enrollment:

Participant gender:

Summary

To investigate the efficacy and safety of PARIET twice daily (b.i.d.) in patients with Proton Pump Inhibitor-resistant reflux esophagitis

Details

Lead Sponsor:

Eisai Co., Ltd.

Treatments:

Rabeprazole